FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804865139> ?p ?o ?g. }

• W2804865139 abstract "ABSTRACT Passive immunotherapy against HIV-1 will most likely require broadly neutralizing antibodies (bnAbs) with maximum breadth and potency to ensure therapeutic efficacy. Recently, the novel CD4 binding site antibody N6 demonstrated extraordinary neutralization breadth and potency against large panels of cross-clade pseudoviruses. We evaluated the in vivo antiviral activity of N6-LS, alone or in combination with the established V3-glycan antibody PGT121, in chronically simian-human immunodeficiency virus (SHIV)-SF162P3-infected macaques. A single dose of N6-LS suppressed plasma viral loads in 4 out of 5 animals at day 7, while the combination of both antibodies suppressed all animals. The combination of both antibodies had no additive antiviral effect compared to a single dose of PGT121, potentially reflecting the nearly 10-fold-higher potency of PGT121 against this SHIV. Viral rebound occurred in the majority of suppressed animals and was linked to declining plasma bnAb levels over time. In addition to the effect on plasma viremia, bnAb administration resulted in significantly reduced proviral DNA levels in PBMCs after 2 weeks and in lymph nodes after 10 weeks. Autologous neutralizing antibody (nAb) responses and CD8 + T-cell responses were not significantly enhanced in the bnAb-treated animals compared to control animals, arguing against their contribution to the viral effects observed. These results confirm the robust antiviral activity of N6-LS in vivo , supporting the further clinical development of this antibody. IMPORTANCE Monocloncal antibodies (MAbs) are being considered for passive immunotherapy of HIV-1 infection. A critical requirement for such strategies is the identification of MAbs that recognize the diversity of variants within circulating but also reservoir viruses, and MAb combinations might be needed to achieve this goal. This study evaluates the novel bnAb N6-LS alone or in combination with the bnAb PGT121, in rhesus macaques that were chronically infected with SHIV. The results demonstrate that N6-LS potently suppressed plasma viral loads in the majority of animals but that the combination with PGT121 was not superior to PGT121 alone in delaying time to viral rebound or reducing peripheral blood mononuclear cell (PBMC) or lymph node proviral DNA levels. The occurrence of viral escape variants in an N6-LS-monotreated animal, however, argues for the need to maximize breadth and antiviral efficacy by combining bnAbs for therapeutic indications." @default.
• W2804865139 created "2018-06-01" @default.
• W2804865139 creator A5001818797 @default.
• W2804865139 creator A5011862588 @default.
• W2804865139 creator A5020230187 @default.
• W2804865139 creator A5022401276 @default.
• W2804865139 creator A5026415856 @default.
• W2804865139 creator A5030740162 @default.
• W2804865139 creator A5035689288 @default.
• W2804865139 creator A5039002856 @default.
• W2804865139 creator A5039410492 @default.
• W2804865139 creator A5054247332 @default.
• W2804865139 creator A5056797877 @default.
• W2804865139 creator A5064348390 @default.
• W2804865139 creator A5067989838 @default.
• W2804865139 creator A5068156387 @default.
• W2804865139 creator A5068600436 @default.
• W2804865139 creator A5071657202 @default.
• W2804865139 creator A5076217842 @default.
• W2804865139 creator A5080175927 @default.
• W2804865139 creator A5088965392 @default.
• W2804865139 date "2017-08-15" @default.
• W2804865139 modified "2023-10-05" @default.
• W2804865139 title "Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys" @default.
• W2804865139 cites W1533750546 @default.
• W2804865139 cites W1924338894 @default.
• W2804865139 cites W1965175217 @default.
• W2804865139 cites W1974431423 @default.
• W2804865139 cites W1987510779 @default.
• W2804865139 cites W1989174077 @default.
• W2804865139 cites W2002574877 @default.
• W2804865139 cites W2010959676 @default.
• W2804865139 cites W2024287923 @default.
• W2804865139 cites W2038110764 @default.
• W2804865139 cites W2066082644 @default.
• W2804865139 cites W2077032728 @default.
• W2804865139 cites W2081313987 @default.
• W2804865139 cites W2083726777 @default.
• W2804865139 cites W2096084676 @default.
• W2804865139 cites W2098013141 @default.
• W2804865139 cites W2102022357 @default.
• W2804865139 cites W2104826373 @default.
• W2804865139 cites W2113236498 @default.
• W2804865139 cites W2115951500 @default.
• W2804865139 cites W2118274231 @default.
• W2804865139 cites W2135151522 @default.
• W2804865139 cites W2135847964 @default.
• W2804865139 cites W2142606174 @default.
• W2804865139 cites W2146704167 @default.
• W2804865139 cites W2150001263 @default.
• W2804865139 cites W2155068656 @default.
• W2804865139 cites W2159515958 @default.
• W2804865139 cites W2160925670 @default.
• W2804865139 cites W2161169821 @default.
• W2804865139 cites W2166378435 @default.
• W2804865139 cites W2167867167 @default.
• W2804865139 cites W2200798239 @default.
• W2804865139 cites W2346116821 @default.
• W2804865139 cites W2347047438 @default.
• W2804865139 cites W2473595575 @default.
• W2804865139 cites W2479380438 @default.
• W2804865139 cites W2522575686 @default.
• W2804865139 cites W2551273870 @default.
• W2804865139 cites W2551392248 @default.
• W2804865139 cites W2557191642 @default.
• W2804865139 cites W2572760626 @default.
• W2804865139 cites W2597074085 @default.
• W2804865139 cites W30316958 @default.
• W2804865139 doi "https://doi.org/10.1128/jvi.00498-17" @default.
• W2804865139 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5533891" @default.
• W2804865139 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28539448" @default.
• W2804865139 hasPublicationYear "2017" @default.
• W2804865139 type Work @default.
• W2804865139 sameAs 2804865139 @default.
• W2804865139 citedByCount "39" @default.
• W2804865139 countsByYear W28048651392018 @default.
• W2804865139 countsByYear W28048651392019 @default.
• W2804865139 countsByYear W28048651392020 @default.
• W2804865139 countsByYear W28048651392021 @default.
• W2804865139 countsByYear W28048651392022 @default.
• W2804865139 countsByYear W28048651392023 @default.
• W2804865139 crossrefType "journal-article" @default.
• W2804865139 hasAuthorship W2804865139A5001818797 @default.
• W2804865139 hasAuthorship W2804865139A5011862588 @default.
• W2804865139 hasAuthorship W2804865139A5020230187 @default.
• W2804865139 hasAuthorship W2804865139A5022401276 @default.
• W2804865139 hasAuthorship W2804865139A5026415856 @default.
• W2804865139 hasAuthorship W2804865139A5030740162 @default.
• W2804865139 hasAuthorship W2804865139A5035689288 @default.
• W2804865139 hasAuthorship W2804865139A5039002856 @default.
• W2804865139 hasAuthorship W2804865139A5039410492 @default.
• W2804865139 hasAuthorship W2804865139A5054247332 @default.
• W2804865139 hasAuthorship W2804865139A5056797877 @default.
• W2804865139 hasAuthorship W2804865139A5064348390 @default.
• W2804865139 hasAuthorship W2804865139A5067989838 @default.
• W2804865139 hasAuthorship W2804865139A5068156387 @default.
• W2804865139 hasAuthorship W2804865139A5068600436 @default.
• W2804865139 hasAuthorship W2804865139A5071657202 @default.
• W2804865139 hasAuthorship W2804865139A5076217842 @default.
• W2804865139 hasAuthorship W2804865139A5080175927 @default.

• next